Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP reduced its holdings in Rockwell Medical, Inc. (NASDAQ:RMTI) by 51.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,590 shares of the company’s stock after selling 92,766 shares during the quarter. GSA Capital Partners LLP owned about 0.29% of Rockwell Medical worth $352,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Concurrent Investment Advisors LLC purchased a new stake in Rockwell Medical during the third quarter worth about $40,000. Beacon Financial Advisory LLC acquired a new stake in shares of Rockwell Medical in the 3rd quarter worth approximately $98,000. Vanguard Group Inc. grew its holdings in shares of Rockwell Medical by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock worth $1,856,000 after acquiring an additional 43,302 shares during the period. Renaissance Technologies LLC increased its stake in Rockwell Medical by 877.1% in the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after purchasing an additional 92,189 shares in the last quarter. Finally, Armistice Capital LLC raised its holdings in Rockwell Medical by 22.5% during the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after purchasing an additional 592,000 shares during the last quarter. 23.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on RMTI shares. RODMAN&RENSHAW raised Rockwell Medical to a “strong-buy” rating in a report on Thursday, November 14th. StockNews.com cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Rockwell Medical in a research report on Wednesday, September 11th. Finally, Rodman & Renshaw began coverage on shares of Rockwell Medical in a research report on Thursday, November 14th. They issued a “buy” rating and a $5.00 price target on the stock.

Rockwell Medical Stock Up 2.3 %

RMTI opened at $2.25 on Friday. The firm has a market cap of $72.72 million, a P/E ratio of -44.00 and a beta of 1.50. The business’s fifty day simple moving average is $3.56 and its 200 day simple moving average is $2.63. Rockwell Medical, Inc. has a 52 week low of $1.16 and a 52 week high of $5.15. The company has a quick ratio of 2.00, a current ratio of 2.41 and a debt-to-equity ratio of 0.33.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.